Garcia-Vidal, Carolina http://orcid.org/0000-0002-8915-0683
Teijón-Lumbreras, Christian
Aiello, Tommaso Francesco
Chumbita, Mariana
Menendez, Rosario
Mateu-Subirà, Aina
Peyrony, Olivier
Monzó, Patricia
Lopera, Carlos
Gallardo-Pizarro, Antonio
Méndez, Raúl
Calbo, Esther
Xercavins, Mariona
Cuesta-Chasco, Genoveva
Martínez, José A.
Marcos, Ma Angeles
Mensa, Josep
Soriano, Alex
Funding for this research was provided by:
Instituto de Salud Carlos III (FIS PI21/01640)
Agència de Gestió d'Ajuts Universitaris i de Recerca (SGR 01324 Q5856414G)
Ligue Contre le Cancer (AAPMRC 2022/OP)
Article History
Received: 12 December 2023
Accepted: 5 February 2024
First Online: 15 March 2024
Declarations
:
: Carolina Garcia Vidal has received honoraria for talks on behalf of Gilead Science, MSD, Pfizer, Jannsen, Novartis, Basilea, GSK, Shionogi, AbbVie, Advanz Pharma, and a grant support from Gilead Science, Pfizer, GSK, MSD and Pharmamar. Alex Soriano has received honoraria for talks on behalf of Merck Sharp and Dohme, Pfizer, Novartis, and Angelini, as well as grant support from Pfizer. Alex Soriano is an Editor-in-Chief of<i> Infectious Diseases and Therapy</i>. Alex Soriano was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Olivier Peyrony has received honoraria for talks on behalf of BMS and Qiagen, and expertise for Sanofi. Other authors do not declare any conflict of interest.
: The Institutional Ethics Committee of the Hospital Clinic of Barcelona approved the study and, as a result of the nature of the retrospective data review, waived the need for informed consent from individual patients (HCB/2020/0273).